Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Outcomes Following Macrolide Use in Kidney Transplant Recipients.

Jeong R, Quinn RR, Lentine KL, Lloyd A, Ravani P, Hemmelgarn B, Braam B, Garg AX, Wen K, Wong-Chan A, Gourishankar S, Lam NN.

Can J Kidney Health Dis. 2019 Feb 21;6:2054358119830706. doi: 10.1177/2054358119830706. eCollection 2019.

2.

Long-term follow-up of the DeKAF cross-sectional cohort study.

Matas AJ, Fieberg A, Mannon RB, Leduc R, Grande J, Kasiske BL, Cecka M, Gaston R, Hunsicker L, Connett J, Cosio F, Gourishankar S, Rush D.

Am J Transplant. 2019 May;19(5):1432-1443. doi: 10.1111/ajt.15204. Epub 2019 Jan 24.

PMID:
30506642
3.

Follow-up Care of Living Kidney Donors in Alberta, Canada.

Lam NN, Lentine KL, Hemmelgarn B, Klarenbach S, Quinn RR, Lloyd A, Gourishankar S, Garg AX.

Can J Kidney Health Dis. 2018 Jul 26;5:2054358118789366. doi: 10.1177/2054358118789366. eCollection 2018.

4.

Late graft failure after kidney transplantation as the consequence of late versus early events.

Gaston RS, Fieberg A, Hunsicker L, Kasiske BL, Leduc R, Cosio FG, Gourishankar S, Grande J, Mannon RB, Rush D, Cecka JM, Connett J, Matas AJ.

Am J Transplant. 2018 May;18(5):1158-1167. doi: 10.1111/ajt.14590. Epub 2017 Dec 5.

5.

Complications in the 90-day postoperative period following kidney transplant and the relationship of the Charlson Comorbidity Index.

Levine MA, Schuler T, Gourishankar S.

Can Urol Assoc J. 2017 Dec;11(12):388-393. doi: 10.5489/cuaj.4378. Epub 2017 Nov 1.

6.

Magnetic resonance imaging artifact following anterior cervical discectomy and fusion with a trabecular metal cage.

Elliott CA, Fox R, Ashforth R, Gourishankar S, Nataraj A.

J Neurosurg Spine. 2016 Mar;24(3):496-501. doi: 10.3171/2015.5.SPINE14219. Epub 2015 Nov 27.

PMID:
26613279
7.

Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.

Knoll GA, Fergusson D, Chassé M, Hebert P, Wells G, Tibbles LA, Treleaven D, Holland D, White C, Muirhead N, Cantarovich M, Paquet M, Kiberd B, Gourishankar S, Shapiro J, Prasad R, Cole E, Pilmore H, Cronin V, Hogan D, Ramsay T, Gill J.

Lancet Diabetes Endocrinol. 2016 Apr;4(4):318-26. doi: 10.1016/S2213-8587(15)00368-X. Epub 2015 Oct 23.

PMID:
26608067
8.

Exercise training improves aerobic capacity, muscle strength, and quality of life in renal transplant recipients.

Riess KJ, Haykowsky M, Lawrance R, Tomczak CR, Welsh R, Lewanczuk R, Tymchak W, Haennel RG, Gourishankar S.

Appl Physiol Nutr Metab. 2014 May;39(5):566-71. doi: 10.1139/apnm-2013-0449. Epub 2013 Nov 28.

PMID:
24766239
9.

The potential impact of delayed radiation therapy on patients with glioblastoma.

Alnaami I, VanderPluym J, Murtha A, Walling S, Mehta V, Gourishankar S, Senthilselvan A.

Can J Neurol Sci. 2013 Nov;40(6):790-4.

PMID:
24257218
10.

Effectiveness of adjuvant temozolomide treatment in patients with glioblastoma.

Alnaami IM, Al-Nuaimi SK, Senthilselvan A, Murtha AD, Walling S, Mehta V, Gourishankar S.

Neurosciences (Riyadh). 2013 Oct;18(4):349-55.

PMID:
24141458
11.

Prediction of kidney graft failure using clinical scoring tools.

Gourishankar S, Grebe SO, Mueller TF.

Clin Transplant. 2013 Jul-Aug;27(4):517-22. doi: 10.1111/ctr.12135. Epub 2013 Jun 3.

PMID:
23731367
12.

Acute renal failure in a kidney donor.

Saliba KA, Colak A, Gourishankar S, Mengel M.

Am J Transplant. 2012 Nov;12(11):3158-60. doi: 10.1111/j.1600-6143.2012.04280.x. No abstract available.

13.

Evaluating the utility of ambulatory blood pressure monitoring in kidney transplant recipients.

Wen KC, Gourishankar S.

Clin Transplant. 2012 Sep-Oct;26(5):E465-70. doi: 10.1111/ctr.12009..

PMID:
23061756
14.

Severe Legionnaire's disease caused by Legionella longbeachae in a long-term renal transplant patient: the importance of safe living strategies after transplantation.

Wright AJ, Humar A, Gourishankar S, Bernard K, Kumar D.

Transpl Infect Dis. 2012 Aug;14(4):E30-3. doi: 10.1111/j.1399-3062.2012.00755.x. Epub 2012 Jun 11.

PMID:
22686947
15.

Optimal cutoff point for immunoperoxidase detection of C4d in the renal allograft: results from a multicenter study.

Crary GS, Raissian Y, Gaston RC, Gourishankar SM, Leduc RE, Mannon RB, Matas AJ, Grande JP.

Transplantation. 2010 Nov 27;90(10):1099-105. doi: 10.1097/TP.0b013e3181f7fec9.

16.

The role of proton pump inhibitors on early mycophenolic acid exposure in kidney transplantation: evidence from the CLEAR study.

Kiberd BA, Wrobel M, Dandavino R, Keown P, Gourishankar S.

Ther Drug Monit. 2011 Feb;33(1):120-3. doi: 10.1097/FTD.0b013e318206a1b1.

PMID:
21192310
17.

Inflammation in areas of tubular atrophy in kidney allograft biopsies: a potent predictor of allograft failure.

Mannon RB, Matas AJ, Grande J, Leduc R, Connett J, Kasiske B, Cecka JM, Gaston RS, Cosio F, Gourishankar S, Halloran PF, Hunsicker L, Rush D; DeKAF Investigators.

Am J Transplant. 2010 Sep;10(9):2066-73. doi: 10.1111/j.1600-6143.2010.03240.x.

18.

Canadian Society of Transplantation and Canadian Society of Nephrology commentary on the 2009 KDIGO clinical practice guideline for the care of kidney transplant recipients.

Knoll GA, Blydt-Hansen TD, Campbell P, Cantarovich M, Cole E, Fairhead T, Gill JS, Gourishankar S, Hebert D, Hodsman A, House AA, Humar A, Karpinski M, Kim SJ, Mainra R, Prasad GV.

Am J Kidney Dis. 2010 Aug;56(2):219-46. doi: 10.1053/j.ajkd.2010.05.004. No abstract available.

PMID:
20659623
19.

The CLEAR study: a 5-day, 3-g loading dose of mycophenolate mofetil versus standard 2-g dosing in renal transplantation.

Gourishankar S, Houde I, Keown PA, Landsberg D, Cardella CJ, Barama AA, Dandavino R, Shoker A, Pirc L, Wrobel MM, Kiberd BA.

Clin J Am Soc Nephrol. 2010 Jul;5(7):1282-9. doi: 10.2215/CJN.09091209. Epub 2010 May 24.

20.

Attitudes and opinions on organ donation: an opportunity to educate in a Canadian city.

Lee E, Midodizi W, Gourishankar S.

Clin Transplant. 2010 Nov-Dec;24(6):E223-9. doi: 10.1111/j.1399-0012.2010.01260.x.

PMID:
20482560
21.

Evidence for antibody-mediated injury as a major determinant of late kidney allograft failure.

Gaston RS, Cecka JM, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Grande J, Halloran P, Hunsicker L, Mannon R, Rush D, Matas AJ.

Transplantation. 2010 Jul 15;90(1):68-74. doi: 10.1097/TP.0b013e3181e065de.

PMID:
20463643
22.

The prognostic utility of deceased donor implantation biopsy in determining function and graft survival after kidney transplantation.

Cockfield SM, Moore RB, Todd G, Solez K, Gourishankar S.

Transplantation. 2010 Mar 15;89(5):559-66. doi: 10.1097/TP.0b013e3181ca7e9b.

PMID:
20110855
23.

Pathological and clinical characterization of the 'troubled transplant': data from the DeKAF study.

Gourishankar S, Leduc R, Connett J, Cecka JM, Cosio F, Fieberg A, Gaston R, Halloran P, Hunsicker L, Kasiske B, Rush D, Grande J, Mannon R, Matas A.

Am J Transplant. 2010 Feb;10(2):324-30. doi: 10.1111/j.1600-6143.2009.02954.x. Epub 2010 Jan 5.

24.

Histopathologic clusters differentiate subgroups within the nonspecific diagnoses of CAN or CR: preliminary data from the DeKAF study.

Matas AJ, Leduc R, Rush D, Cecka JM, Connett J, Fieberg A, Halloran P, Hunsicker L, Cosio F, Grande J, Mannon R, Gourishankar S, Gaston R, Kasiske B.

Am J Transplant. 2010 Feb;10(2):315-23. doi: 10.1111/j.1600-6143.2009.02943.x. Epub 2009 Dec 23.

25.

Use of cardioprotective medications in kidney transplant recipients.

Gaston RS, Kasiske BL, Fieberg AM, Leduc R, Cosio FC, Gourishankar S, Halloran P, Hunsicker L, Rush D, Matas AJ.

Am J Transplant. 2009 Aug;9(8):1811-5. doi: 10.1111/j.1600-6143.2009.02696.x. Epub 2009 Jun 10.

26.

Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient.

Kumar D, Gourishankar S, Mueller T, Cockfield S, Weinkauf J, Vethanayagam D, Humar A.

Transpl Infect Dis. 2009 Apr;11(2):167-70. doi: 10.1111/j.1399-3062.2008.00345.x. Epub 2008 Sep 18.

PMID:
18803617
27.

Non-melanoma skin cancer incidence and risk factors after kidney transplantation: a Canadian experience.

Comeau S, Jensen L, Cockfield SM, Sapijaszko M, Gourishankar S.

Transplantation. 2008 Aug 27;86(4):535-41. doi: 10.1097/TP.0b013e318180482d.

PMID:
18724222
28.

The use of donor and recipient screening for toxoplasma in the era of universal trimethoprim sulfamethoxazole prophylaxis.

Gourishankar S, Doucette K, Fenton J, Purych D, Kowalewska-Grochowska K, Preiksaitis J.

Transplantation. 2008 Apr 15;85(7):980-5. doi: 10.1097/TP.0b013e318169bebd.

PMID:
18408578
29.

Serum cystatin C performs similarly to traditional markers of kidney function in the evaluation of donor kidney function prior to and following unilateral nephrectomy.

Gourishankar S, Courtney M, Jhangri GS, Cembrowski G, Pannu N.

Nephrol Dial Transplant. 2008 Sep;23(9):3004-9. doi: 10.1093/ndt/gfn114. Epub 2008 Mar 14.

PMID:
18344244
30.

The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design.

Knoll GA, Cantarovitch M, Cole E, Gill J, Gourishankar S, Holland D, Kiberd B, Muirhead N, Prasad R, Tibbles LA, Treleaven D, Fergusson D.

Nephrol Dial Transplant. 2008 Jan;23(1):354-8. Epub 2007 Sep 10.

PMID:
17848393
31.

Quality of care among Aboriginal hemodialysis patients.

Chou SH, Tonelli M, Bradley JS, Gourishankar S, Hemmelgarn BR; Alberta Kidney Disease Network.

Clin J Am Soc Nephrol. 2006 Jan;1(1):58-63. Epub 2005 Nov 9.

32.

Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients.

Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.

Transplantation. 2007 Jun 27;83(12):1648-51.

PMID:
17589351
33.

Patient and allograft survival of Indo Asian and East Asian dialysis patients treated in Canada.

Tonelli M, Hemmelgarn B, Gill JS, Chou S, Culleton B, Klarenbach S, Manns B, Wiebe N, Gourishankar S; Alberta Kidney Disease Network.

Kidney Int. 2007 Aug;72(4):499-504. Epub 2007 Jun 6.

34.

Differences in use of peritoneal dialysis and survival among East Asian, Indo Asian, and white ESRD patients in Canada.

Hemmelgarn BR, Chou S, Wiebe N, Culleton BF, Manns BJ, Klarenbach S, Khan NA, Gourishankar S, Yeates KE, Gill JS, Tonelli M.

Am J Kidney Dis. 2006 Dec;48(6):964-71. Erratum in: Am J Kidney Dis. 2007 Feb;49(2):348.

PMID:
17162151
35.

Impaired arterial compliance and aerobic endurance in kidney transplant recipients.

Riess KJ, Gourishankar S, Oreopoulos A, Jones LW, McGavock JM, Lewanczuk RZ, Haykowsky MJ.

Transplantation. 2006 Oct 15;82(7):920-3.

PMID:
17038907
36.

Factors associated with publication following presentation at a transplantation meeting.

Glick N, MacDonald I, Knoll G, Brabant A, Gourishankar S.

Am J Transplant. 2006 Mar;6(3):552-6.

37.

Wait-listing for kidney transplantation among Aboriginal hemodialysis patients.

Tonelli M, Chou S, Gourishankar S, Jhangri GS, Bradley J, Hemmelgarn B; Alberta Kidney Disease Network.

Am J Kidney Dis. 2005 Dec;46(6):1117-23.

PMID:
16310578
38.

Long-term deterioration of kidney allograft function.

Kasiske BL, Gaston RS, Gourishankar S, Halloran PF, Matas AJ, Jeffery J, Rush D.

Am J Transplant. 2005 Jun;5(6):1405-14.

39.

Conversion of stable kidney transplant recipients from a twice daily Prograf-based regimen to a once daily modified release tacrolimus-based regimen.

Alloway R, Steinberg S, Khalil K, Gourishankar S, Miller J, Norman D, Hariharan S, Pirsch J, Matas A, Zaltzman J, Wisemandle K, Fitzsimmons W, First MR.

Transplant Proc. 2005 Mar;37(2):867-70.

PMID:
15848559
40.

Herpes simplex virus seroprevalence and risk factors in 2 Canadian sexually transmitted disease clinics.

Singh AE, Romanowski B, Wong T, Gourishankar S, Myziuk L, Fenton J, Preiksaitis JK.

Sex Transm Dis. 2005 Feb;32(2):95-100.

PMID:
15668615
41.

Use and outcomes of peritoneal dialysis among Aboriginal people in Canada.

Tonelli M, Hemmelgarn B, Manns B, Davison S, Bohm C, Gourishankar S, Pylypchuk G, Yeates K, Gill JS.

J Am Soc Nephrol. 2005 Feb;16(2):482-8. Epub 2004 Dec 8.

42.

Development of diabetes mellitus following kidney transplantation: a Canadian experience.

Gourishankar S, Jhangri GS, Tonelli M, Wales LH, Cockfield SM.

Am J Transplant. 2004 Nov;4(11):1876-82.

43.

Death and renal transplantation among Aboriginal people undergoing dialysis.

Tonelli M, Hemmelgarn B, Manns B, Pylypchuk G, Bohm C, Yeates K, Gourishankar S, Gill JS.

CMAJ. 2004 Sep 14;171(6):577-82.

44.

Extended reuse of polysulfone hemodialysis membranes using citric acid and heat.

Tonelli M, Dymond C, Gourishankar S, Jindal KK.

ASAIO J. 2004 Jan-Feb;50(1):98-101.

PMID:
14763499
45.

Peritubular capillary changes and C4d deposits are associated with transplant glomerulopathy but not IgA nephropathy.

Vongwiwatana A, Gourishankar S, Campbell PM, Solez K, Halloran PF.

Am J Transplant. 2004 Jan;4(1):124-9.

46.

Herpes zoster infection following solid organ transplantation: incidence, risk factors and outcomes in the current immunosuppressive era.

Gourishankar S, McDermid JC, Jhangri GS, Preiksaitis JK.

Am J Transplant. 2004 Jan;4(1):108-15.

47.

Transplant Friends: an interactive education program for patients awaiting kidney transplantation.

Sharkey C, Gourishankar S.

Transplant Proc. 2003 Nov;35(7):2405-6.

PMID:
14611970
48.

The stability of the glomerular filtration rate after renal transplantation is improving.

Gourishankar S, Hunsicker LG, Jhangri GS, Cockfield SM, Halloran PF.

J Am Soc Nephrol. 2003 Sep;14(9):2387-94.

49.

Do cardiac troponins provide prognostic insight in hemodialysis patients?

Choy JB, Armstrong PW, Ulan RA, Campbell PM, Gourishankar S, Prosser CI, Tymchak WJ.

Can J Cardiol. 2003 Jul;19(8):907-11.

PMID:
12876611
50.

Donor tissue characteristics influence cadaver kidney transplant function and graft survival but not rejection.

Gourishankar S, Jhangri GS, Cockfield SM, Halloran PF.

J Am Soc Nephrol. 2003 Feb;14(2):493-9.

Supplemental Content

Loading ...
Support Center